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ABSTRACT: Regulation of excitatory to inhibitory signaling balance is essential to nervous system health and is maintained by numerous
enzyme systems that modulate the activity, localization, and abundance of synaptic proteins. SUMOylation is a key post-translational regulator of
protein function in diverse cells, including neurons. There, its role in regulating synaptic transmission through pre- and postsynaptic effects has
been shown primarily at glutamatergic central nervous system synapses, where the sole SUMO-conjugating enzyme Ubc9 is a critical player.
However, whether Ubc9 functions globally at other synapses, including inhibitory synapses, has not been explored. Here, we investigated the
role of UBC-9 and the SUMOylation pathway in controlling the balance of excitatory cholinergic and inhibitory GABAergic signaling required for
muscle contraction in Caenorhabditis elegans. We found inhibition or overexpression of UBC-9 in neurons modestly increased muscle excitation.
Similar and even stronger phenotypes were seen with UBC-9 overexpression specifically in GABAergic neurons, but not in cholinergic neurons.
These effects correlated with accumulation of synaptic vesicle-associated proteins at GABAergic presynapses, where UBC-9 and the C. elegans
SUMO ortholog SMO-1 localized, and with defects in GABA-dependent behaviors. Experiments involving expression of catalytically inactive
UBC-9 [UBC-9(C93S)], as well as co-expression of UBC-9 and SMO-1, suggested wild type UBC-9 overexpressed alone may act via substrate
sequestration in the absence of sufficient free SUMO, underscoring the importance of tightly regulated SUMO enzyme function. Similar effects on
muscle excitation, GABAergic signaling, and synaptic vesicle localization occurred with overexpression of the SUMO activating enzyme subunit
AOS-1. Together, these data support a model in which UBC-9 and the SUMOylation system act at presynaptic sites in inhibitory motor neurons to
control synaptic signaling balance in C. elegans. Future studies will be important to define UBC-9 targets at this synapse, as well as mechanisms
by which UBC-9 and the SUMO pathway are regulated.
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Significance statement

•• Identifies a presynaptic role for the SUMO enzyme system
in inhibitory neurons during neuromuscular signaling.
•• Shows SUMO E2 UBC-9 localizes to GABAergic
motor neuron presynapses and affects vesicle localization
and muscle excitation.
•• Aids understanding of conserved UBC-9 functions in
E:I balance, which is lost in neurological diseases.

Introduction

Excitatory to inhibitory (E:I) signaling balance is critical for
nervous system function, and many neurological diseases,
including epilepsy, autism, and numerous neurodegenerative
conditions, involve E:I imbalances.1,2 Hundreds of proteins
reside at pre- and postsynaptic sites to control the amount and
timing of signaling at specific synapses, contributing to regulation of this balance.3 A variety of post-translational modifications, including phosphorylation, ubiquitination, and
palmitoylation tightly control the functions of synaptic proteins.4-8 Many of these modifications are activity-dependent
and serve to modulate the localization, surface expression,
activity, and/or complex formation of synaptic proteins to
impact synaptic vesicle release and neurotransmitter signal
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reception.4,9–15 The extent of these modifications, as well as the
specific enzymes and target proteins involved, remain incompletely understood.
Protein SUMOylation is a post-translational modification, conserved from yeast to humans, that has emerged as a
key regulator of neuronal and synaptic biology.8,16–18 During
SUMOylation, proteins are modified by the covalent attachment of small ubiquitin-like modifier (SUMO) polypeptides. These approximately 100-amino acid globular SUMO
molecules (SUMO-1, -2/3, and -4 in humans) are similar in
size and shape to ubiquitin and are likewise added to lysine
residues in target proteins through the activity of a multistep enzymatic cascade. For SUMO, this involves activation
of mature SUMO molecules by the E1 enzyme complex
Aos1-Uba2 /SAE1-SAE2 followed by SUMO transfer to
the E2 SUMO-conjugating enzyme Ubc9.16,19 Ubc9 alone,
or in combination with any of a number of E3 ligases, mediates the attachment of SUMO to the target protein.19
Removal of SUMO peptides from substrates, as well as
activation of immature SUMO peptides, occurs via the
activity of SUMO isopeptidases, also known as ubiquitinlike-specific proteases (Ulp) or sentrin-specific proteases
(SENPs).19,20
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Originally identified for its role in regulating transcriptional
activity and other nuclear functions, SUMOylation is now
known to modulate the activity and localization of diverse
cytosolic proteins, including many involved in neuronal and
synapse physiology.8,17 Several known SUMOylated neuronal
proteins, including huntingtin, amyloid precursor protein,
ataxins, tau, alpha-synuclein, and BACE1, are linked to neurodegenerative diseases.18,21,22 SUMO-1 has also been detected
in synaptosomes from mouse models of Alzheimer’s Disease,23
and global SUMOylation levels are reported to be differentially affected by varying levels of oxidative stress, a component
of age- and infection-related neurodegeneration.24 Thus, the
SUMOylation pathway has been proposed as a therapeutic target in these diseases. Biochemical studies of synaptic fractions
from rat hippocampi indicate the presence of multiple
SUMOylated synaptic proteins, although the identities of
many of these remain unknown.25 Synaptic proteins shown to
be regulated by SUMOylation, primarily at mammalian glutamatergic synapses, include postsynaptic scaffold proteins
CASK and GISP,11,26 along with a number of presynaptic regulators of vesicle release.9,10,27,28 Data from other studies indicate certain K+ and Na+ channels also are regulated either
directly or indirectly via SUMOylation to promote general
neuronal excitability, as is the AMPA receptor regulator
Arc.16,29 Together these data demonstrate the importance of
protein SUMOylation in controlling synaptic function at central synapses.
Because it is the sole E2 SUMO conjugating enzyme in any
organism, Ubc9 represents a critical component of the SUMO
pathway. Ubc9 activity itself is regulated by SUMOylation, as
well as by phosphorylation and acetylation.30–33 Ubc9 typically
localizes to sites where SUMO is found,18 and organisms lacking Ubc9 are not viable, suggesting the importance of
SUMOylation in development.34–36 Multiple studies also have
implicated Ubc9 in synaptic function and plasticity. Work in
Drosophila uncovered a genetic requirement for Ubc9 in long
term memory formation where it appears to act with histone
deacetylase 4 (HDAC4).37 Studies in rat hippocampal neurons
demonstrated the ability of Ubc9 to interact with GluR6 kainate receptor subunits, which are SUMOylated following kainate application to promote postsynaptic receptor internalization
and decreased kainate-evoked currents.38 Activity-dependent
pre- and post-synaptic localization of Ubc9, as well as other
SUMOylation and deSUMOylation machinery, at glutamatergic central synapses was confirmed by several other studies.11,13–15,25 These reports underscore the importance of Ubc9
and SUMOylation to synaptic function. However, questions as
to whether Ubc9’s role is conserved across phylogeny and at
diverse synapse types, including at inhibitory or peripheral synapses, remain. Just one study to date has described a role for the
SUMO system at GABAergic synapses, where it regulates the
postsynaptic GABAA receptor scaffold protein gephyrin,39 and
a single paper identified SUMOylation of a muscarinic
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acetylcholine receptor in heterologous cell culture.40 Moreover,
only a few papers have explored any neuronal SUMO or Ubc9
functions in non-mammalian organisms.37,41–45
The neuromuscular junction (NMJ) of Caenorhabditis elegans is an ideal system in which to investigate the broader regulation of synaptic signaling and E:I balance by the SUMO
pathway. The body wall muscles of these microscopic roundworms contain both excitatory inputs from cholinergic motor
neurons that promote muscle contraction and inhibitory inputs
from GABAergic motor neurons that promote muscle relaxation by counteracting the excitatory signals.46 Tight regulation
of the balance of excitatory and inhibitory transmission is
required for proper muscle contraction and movement of the
worms. Behavioral assays, including sensitivity to paralysis
induced by the acetylcholinesterase inhibitor, aldicarb, can be
used to measure muscle excitation as a readout for neuromuscular signaling balance.47 In the presence of aldicarb, populations of worms paralyze over time. Animals carrying mutations
that increase cholinergic signaling or decrease GABAergic
signaling show increased paralysis relative to wild type worms,
whereas those with decreased cholinergic or increased
GABAergic signaling exhibit decreased paralysis.47 Numerous
genes now known to regulate E:I signaling balance across phylogeny were identified based on the aldicarb phenotypes of
mutant worms.48–50 C. elegans contain homologs of the SUMO
E1 (AOS-1 and UBA-2 subunits) and E2 (UBC-9) enzymes,
as well as homologs of several E3 ligases and SENPs (called
ULPs in C. elegans).34 A single C. elegans SUMO ortholog,
SMO-1, exists and has structural and functional similarity to
SUMO-1 and -2 in humans. The smo-1 gene is essential and
expressed throughout development, and animals lacking smo-1
expression that survive due to maternal contributions are sterile
with abnormal somatic gonads, vulvas, and germlines.51 Other
studies have identified SUMOylated C. elegans proteins,52 and
current estimates indicate as much as 15% to 20% of the worm
proteome is SUMOylated at any given time, similar to estimates in human cells.53,54
In this study, we set out to assess the potential requirements
for the SUMO pathway in controlling E:I balance at the C.
elegans NMJ. Given the localization of Ubc9 to synapses in
mammalian neurons and the general importance of presynaptic
protein SUMOylation for neurotransmitter release at glutamatergic hippocampal synapses, we hypothesized that SUMO
pathway enzymes are required in motor neurons to maintain
appropriate neuroromuscular E:I signaling balance and muscle
excitation. Here, we show that the SUMO-conjugating enzyme
UBC-9 can act in GABAergic neurons to regulate neuromuscular function. Overexpressed UBC-9 localized to presynaptic
sites in GABAergic motor neurons, caused accumulation of
GABA-containing synaptic vesicles, and increased muscle
contraction, changes that correlated with defects in a pharmacologic test of GABAergic signaling. Similar results were seen
with overexpression of the SUMO E1 subunit AOS-1,
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supporting a role for the SUMO pathway beyond just UBC-9.
Enhanced muscle contraction also was seen with inhibition of
UBC-9 or AOS-1 expression, as well as with overexpression of
a SUMO conjugation-deficient UBC-9, consistent with dominant negative substrate sequestration effects. Overexpression of
SMO-1 also modestly increased muscle excitation in a manner
non-additive with UBC-9 overexpression, suggesting UBC-9
and SMO-1 act in a common pathway to impact neuromuscular function and further underscoring the need for precise control of SUMO enzyme activity at this synapse. Based on these
data, we propose that endogenous UBC-9 acts in GABAergic
neurons, likely via a SUMO-dependent pathway, to promote
appropriate levels GABA neurotransmitter release and prevent
excess muscle contraction. Our results are consistent with those
of prior studies that demonstrate the critical need for tight
regulation of synaptic protein SUMOylation and SUMO
enzyme function for proper synaptic signaling.

Materials and Methods
C. elegans strains
All strains were grown on nematode growth medium (NGM)
agar plates spotted with OP50 Escherichia coli and maintained
at 20°C according to standard protocols.55 Young adult hermaphrodite worms were used for all experiments. Table 1 lists
the strains used in this study.

Plasmid and strain generation
The Psnb-1::ubc-9 (pJRK22) and Psnb-1::aos-1 (pJRK23) plasmids were made by inserting ubc-9 or aos-1 cDNA, respectively, into the PD49.26 plasmid56 containing the Psnb-1
promoter (pFJ19). To do this, the cDNAs were amplified from
the Vidal Orfeome clones (F29B9.6 and C08B6.9) using forward and reverse primers engineered with NheI and KpnI
restriction sites. The amplified PCR products and plasmid
pFJ19 were digested with NheI and KpnI, then the ubc-9 or
aos-1 cDNA was inserted into pFJ19 using T4 DNA ligase. To
make Punc-25::aos-1 (pJRK39), pJRK23 was digested with
SphI and BamHI to remove the Psnb-1 promoter. The Punc25 promoter was isolated from the pJRK8 (Punc25::yfp::emb-27) plasmid using the same enzymes, then ligated
into pJRK23. The Punc-25::ubc-9 (pJRK43) and Punc17::ubc-9 (pJRK44) plasmids were made by inserting the Punc25 and Punc-17 promoters into the PD49.26 plasmid56
containing ubc-9 cDNA. To do this, plasmids pJRK39 and
pJRK42 (Punc-17::aos-1) were digested with SphI and BamHI
to remove the unc-25 and unc-17 promoters, and these were
ligated between the SphI and BamHI sites in pJRK22 following removal of Psnb-1. To generate the Punc-25::ubc-9(C93S)
plasmid (pJRK69), QuikChange site-directed mutagenesis
(Agilent) was performed using primers designed to introduce a
single basepair mutation into the ubc-9 sequence (forward
primer:
5’-cccatcaggtaccgtgAgcttatctcttctgga-3’;
reverse
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primer: 5’-tccagaagagataagcTcacggtacctgatggg-3) and performed according to the manufacturer’s instructions. The
Punc-25::gfp::smo-1(GG) (pJRK81) plasmid was made by
inserting gfp::smo-1(GG) amplified from pJRK72 [previously
generated from plasmid #462]57into plasmid pJRK39 using gfp
forward and smo-1 reverse primers containing NheI and KpnI
restriction sites, respectively. The PCR products and pJRK39
were digested with NheI and KpnI. This removed aos-1 from
pJRK39 and allowed for the subsequent insertion of gfp::smo-1
into pJRK39 using T4 DNA ligase. The final pJRK81 plasmid
was confirmed by sequencing. The Punc-25::gfp::ubc-9
(pJRK85) plasmid was constructed in 2 steps. First, ubc-9
cDNA containing an internal NotI restriction site at the
N-terminus was generated via PCR amplification of ubc-9
from pJRK43 using forward and reverse primers containing
NheI and SacI restriction sites, respectively. Plasmid pJRK39
and the amplified [ubc-9(NotI)] products were then digested
with NheI and SacI to remove the aos-1 cDNA from pJRK39
and to create restriction sites on the ubc-9(NotI) insert, and the
two fragments were ligated to create Punc-25::ubc-9(NotI)
(pJRK80). Second, pJRK80 and pJRK50 (Pfshr-1::gfp::fshr-1)
were digested with NotI to remove gfp. Following heat inactivation, the digested pJRK80 was treated with calf intestinal
alkaline phosphatase. pJRK85 was created by ligating gfp into
the NotI site in pJRK80.
Transgenic strains with panneuronal, GABAergic, or cholinergic neuron-specific UBC-9, UBC-9(C93S), AOS-1, or
SMO-1(GG) overexpression were isolated following standard
microinjection of the plasmids into the gonads of gravid N2
adult worms as described previously and at concentrations that
generated viable lines for each transgene.58 Psnb-1::ubc-9
(pJRK22) and Psnb-1::aos-1 (pJRK23) were each injected at a
concentration of 1 ng/μL, along with 10 ng/μL of Pmyo2::NLS::gfp (co-injection marker) to generate strains JRK71and
JRK50, respectively. Punc-25::aos-1 (pJRK39) was injected at
25 ng/µL, along with 10 ng/µL of Pmyo-2::NLS::gfp to generate strain JRK70. Punc-25::ubc-9 (pJRK43) was injected at a
concentration of 10 ng/μL, along with 10 ng/μL of Pmyo2::NLS::gfp (co-injection marker) to generate strain JRK72 or
with 50 ng/μL of Pttx3::dsRed to generate JRK137. Punc17::ubc-9 (pJRK44) was injected at 20 ng/µL, along with 10 ng/
µL of Pmyo-2::NLS::gfp to generate strain JRK102. The Punc25::ubc-9(C93S) (pJRK69) plasmid, Punc-25::gfp::smo-1(GG)
(pJRK81), and Punc-25::gfp::ubc-9 (pJRK85) were each injected
at a concentration of 10 ng/μL, along with 10 ng/μL of Pmyo2::NLS::gfp (co-injection marker) to generate strains JRK110,
JRK136, and JRK134, respectively. The mock overexpression
(OE) control strain ( JRK64) was generated by injection of
10 ng/µL of Pmyo-2::NLS::gfp alone.

RNA interference
RNA interference (RNAi) was performed as follows using the
feeding method in RNAi-enhanced strains. Panneuronal
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Table 1. C. elegans strains used (*indicates additional times outcrossed to wild type).
Strain number

Genotype

N2 (Bristol)

Wild type

NM467

snb-1(md247)

RB1500

ulp-1(ok1768)

FJ413

ulp-3(tm1287)

FJ415

ulp-1(tm1174)

JRK10

ulp-5(tm3071)*2

JRK18

kjrEx4 (Punc-25::mcherry::snb-1; Pmyo-2::NLS::mcherry)]48

JRK24

ulp-1(ok1768)*3;ulp-3(tm1287)

JRK25

ulp-1(ok1768)*3;ulp-5(tm3071)

JRK34

uIs60 (Punc-119::yfp; Punc-119::sid-1); nre-1(hd120) lin-15(hd126)

JRK48

juIs1*1

JRK50

kjrEx12 (Psnb-1::aos-1; Pmyo-2::NLS::gfp)

JRK64

kjrEx20 (Pmyo-2::NLS::gfp)

JRK68

nuIs152*2

JRK70

kjrEx21 (Punc-25::aos-1; Pmyo-2::NLS::gfp)

JRK71

kjrEx11 (Psnb-1::ubc-9;Pmyo-2::NLS::gfp)

JRK72

kjrEx22 (Punc-25::ubc-9;Pmyo-2::NLS::gfp)

JRK77

kjrEx11; nuIs152

JRK82

kjrEx12; juIs1*2

JRK85

kjrEx21; juIs1*2

JRK86

kjrEx22; juIs1*2

JRK89

kjrEx22;nuIs152

JRK102

kjrEx29 (Punc-17::ubc-9;Pmyo-2::NLS::gfp)]

JRK110

kjrEx31 (Punc-25::ubc-9(C93S); Pmyo-2::NLS::gfp)]

JRK134

kjrEx34 (Punc-25::gfp::ubc-9;Pmyo-2::NLS::gfp)

JRK135

kjrEx35 (Punc-25::gfp::smo-1(GG);Pmyo-2::NLS::gfp) line #1

JRK136

kjrEx36 (Punc-25::gfp::smo-1(GG);Pmyo-2::NLS::gfp) line #2

JRK137

kjrEx37 (Punc-25::ubc-9;Pttx-3::dsRed)

JRK138

kjrEx35; kjrEx37

JRK139

kjrEx4; kjrEx34

JRK141

kjrEx4; kjrEx36

RNAi was performed using the uIs60;nre-1(hd20) lin15b(hd126) strain, which expresses SID-1 RNA channels
under a neuron-specific promoter.59,60 RNAi clones were
obtained from a genome-wide library consisting of HT115(DE)
E. coli carrying gene fragments for double-stranded RNA production in the T7-tailed L4440 vector.61 Bacteria were maintained in the presence of 50 μg/ml ampicillin and 15 μg/ml

tetracycline for plasmid selection.62 RNAi feeding plates were
prepared as follows. First, 3 ml overnight cultures of bacteria
carrying an RNAi plasmid targeting either ubc-9, aos-1, or gfp
(negative control) were grown in Luria broth (LB) containing
50 μg/ml ampicillin. Cultures were spotted (150 μl each) onto
35 mm NGM agar plates containing 50 μg/ml ampicillin and
5 mM IPTG. Plates were dried open for 2 hours, then closed
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and left overnight at room temperature. For panneuronal
RNAi, a <1-generation protocol was used to avoid embryonic
lethality caused by potential knockdown in non-neuronal tissues. Worms were synchronized by bleaching gravid adults to
hatch and recover L1s, which were then plated onto RNAicontaining plates and grown at 20°C for 3 days. For all experiments, RNAi-treated worms were grown to the young adult
stage for use in aldicarb assays.

Aldicarb assays
NGM agar plates (35 mm) containing 1mM of aldicarb
(Sigma-Aldrich) were prepared, then spotted with 150 μL of
OP50 E. coli. After 1 day, approximately 20 young adult worms
were placed on each plate in 2-minute intervals, then measured
for total paralysis every 25 minutes. Total paralysis was defined
as no physical movement of the worms when prodded 3 times
with a platinum wire on the nose.47 Three plates were tested for
each strain of worms per experiment with the experimenter
double-blinded to genotype. The average percentage of worms
paralyzed for each strain at each time point ± s.e.m. was calculated using Microsoft Excel. Data from a total of 3 to 15 plates
were pooled from experiments taken at the same time intervals
over several days. Statistical analyses were performed using
JMP 14 software to compare the average percentages of worms
of each strain paralyzed at the timepoint with the largest differences for each experiment (75 or 100 minutes). All data were
first confirmed to fall within a normal distribution using a
Shapiro Wilk Goodness of Fit test, and equality of variances
confirmed using the Analysis of Means (ANOM) of Variances
test. One-way ANOVAs then were used to assess statistical
significance of the differences in the means between groups
(α < 0.05), followed by a Tukey’s post hoc test (α < 0.05 for
all). Connecting letters reports, as well as p value results of
ordered difference reports are provided.

Pentylenetetrazole assays
NGM agar plates (35 mm) containing 10 mg/ml pentylenetetrazole (PTZ, Sigma-Aldrich) were prepared on the day of the
experiment, allowed to dry open for 1 hour at room temperature, then spotted with 25 μL of OP50 E. coli. After 2 additional hours of drying, approximately 20 (and no less than 15)
young adult worms were placed onto each plate in 4-minute
intervals, then measured for anterior convulsions (“head bobs”)
after 50 minutes.48,63 These anterior convulsions were accompanied by full body paralysis in some animals. Two plates were
tested for each strain of worms per experiment with the experimenter double-blinded to genotype. One plate of worms of
each genotype was also tested on plates containing 0 mg/ml
PTZ to ensure the absence of convulsions. The average percentage of worms exhibiting anterior convulsions for each
strain at each time point ± SD was calculated using Microsoft
Excel. Data from a total of 8 to 10 plates were pooled from
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experiments taken at the same time intervals over several days.
Statistical analyses were performed using JMP 14 software,
with data tested for normality and equality of variances followed by a one-way ANOVA (α < 0.05) and Tukey’s post hoc
test (α < 0.05 for all). Connecting letters reports and p value
results of ordered difference reports are provided.

Fluorescence microscopy
For all imaging experiments, young adult worms were immobilized in 30 mg/ml 2, 3-butanedione monoxamine (SigmaAldrich) for 5 to 7 minutes, then mounted on 2% agarose pads.
Their dorsal nerve cords halfway between the vulva and the tail
were imaged with a Leica DMLB microscope (Leica
Microsystems) with a 100x Plan Apochromat (1.4 NA) objective equipped with green and red fluorescence filters. Images
were captured using an Exi Aqua cooled CCD camera
(Qimaging) with Metamorph (v7.7) software (Molecular
Devices) as described previously.48
Quantitative imaging of GFP::SNB-1 fluorescent puncta in
the dorsal nerve cord of worms overexpressing UBC-9 in all
neurons (kjrEx11) or only in GABA neurons (kjrEx22) was
performed by generating maximum intensity projections of
z-series stacks (0.2 μm steps, 1 μm total depth). Exposure settings, gain, and binning were set to fill a 12-bit dynamic range
without saturation. These settings were identical for all images
taken of a given fluorescent marker [i.e., GFP::SNB-1 in
GABAergic (juIs1) or cholinergic (nuIs152) neurons] for each
imaging set. Linescans of dorsal nerve cord puncta were generated using Metamorph (v7.1) software, and the linescan data
were analyzed with Igor Pro (Wavemetrics) using custom written software as previously described.64 Mercury arc lamp output was normalized by measuring the intensities of 0.5 μm
FluoSphere beads (Invitrogen Life Technologies) for each
imaging day. Puncta intensities were calculated by dividing the
average maximal peak intensity by the average bead intensity
for the corresponding day. Interpunctal axonal intensities were
similarly calculated using the average baseline fluorescence
value within the dorsal nerve cord. Puncta widths were determined by measuring the width of each punctum at half the
maximum peak fluorescence. Puncta densities were determined
by quantifying the average number of puncta per 10 μm of the
dorsal nerve cord. For all data, an average of the values for each
worm in the data set ± s.e.m. is reported. Statistical significance of any differences between wild type and transgenic
strain values was determined in Igor using a one-way ANOVA
with Tukey’s post hoc test (P ⩽ .05). Graphs of puncta intensities, interpunctal axonal fluorescence, and width show data
normalized to wild type values. Images were cropped and set to
matching input levels using Adobe Photoshop.
For colocalization studies, z-stacks were obtained of worms
co-expressing
mCherry::SNB-1
and
GFP::UBC-9
(kjrEx4;kjrEx34) or mCherry::SNB-1 and GFP::SMO-1
(kjrEx4;kjrEx36) over a 2 μm total depth (0.2 μm steps), and

6

Neuroscience Insights

Figure 1. Knockdown of ubc-9 or aos-1 expression in neurons causes increased muscle excitation. Aldicarb assays were performed on animals
neuronally sensitized to RNAi. Worms were fed RNAi-containing bacteria targeting gfp as a negative control, (A) ubc-9, or (B) aos-1 from the L1 stage.
Approximately 20 young adult RNAi-treated worms per plate were exposed to 1 mM aldicarb and paralysis was measured in response to gentle prodding
on the nose with a platinum wire. Representative assays testing 3 plates per strain are shown. Error bars denote s.e.m.

quantification of colocalization was performed using
Metamorph 7.1. An overlaid z-stack image file was created by
merging images taken in each of the red and green channels.
Then, the individual plane in best focus from the merged stacks
of both red and green channel images for each worm was
selected for analysis. Regions containing in-focus puncta were
selected from these single plane images, and the software’s
linescan function was used to measure intensities across these
portions of the image in both the red and green channels. Red
peaks generated from the puncta were counted and recorded,
and individual green peaks were counted and recorded separately. Then, the regions where red and green peaks overlapped,
indicating colocalization of the two fluorophores, were counted.
Only regions at least 5 a.u. greater than the background intensity value were considered as peaks, and red and green peaks
that overlap at least 75% were counted for the colocalization
analysis. The mean percentage of mCherry::SNB-1 peaks
overlapping GFP::UBC-9 or GFP::SMO-1 and the percentage of GFP::UBC-9 or GFP::SMO-1 overlapping with
mCherry::SNB-1 were determined from these counts. To control for potential bleed-through effects, worms overexpressing
just mCherry::SNB-1 (kjrEx4), just GFP::UBC-9 (kjrEx34),
or just GFP::SMO-1 (kjrEx36) were also imaged under both
red and green filters using the same parameters as for the double-transgenic strains (see Supplemental Material). Images were
cropped and set to matching input levels for each channel using
Adobe Photoshop.

Results

We began by assessing whether SUMO pathway enzymes were
required for neuromuscular signaling. To do this, we tested animals with reduced expression of the genes encoding individual
SUMO-activating subunits (AOS-1 and UBA-2), the SUMOconjugating enzyme (UBC-9), the E3 SUMO ligase GEI-17,

or the SUMO proteases (ULP-1, -2, -3, -4 and -5) for paralysis
responses induced by the acetylcholinesterase inhibitor,
aldicarb. In these experiments reduction of gene expression was
induced by either feeding RNAi (aos-1, uba-2, ubc-9, gei-17,
ulp-2, and -4) or genetic mutation (ulp-1, -3, and -5). Individual
inhibition of each of the 5 the proteases led to wild type
aldicarb phenotypes. Wild type phenotypes were also observed
for ulp-1;ulp-3 and ulp-1;ulp-5 genetic double mutant animals,
potentially due to redundancy of protease function (data not
shown). Whereas no consistent results were observed with
knockdown of uba-2 and gei-17, modest aldicarb hypersensitivity was observed with knockdown of ubc-9 or aos-1 relative
to control-treated worms (Figure 1), indicative of increased
muscle contraction. We also observed weak but variable
aldicarb hypersensitivity following cell type-specific knockdown65 of aos-1 or ubc-9 only in GABAergic but not in cholinergic neurons (data not shown), suggesting that ubc-9 activity
may be required specifically in GABAergic neurons to prevent
excess muscle excitation. Due to the modest effects and the
variability inherent in doing cell type-specific RNAi, we centered our subsequent investigations on the possible effects of
SUMO enzyme overexpression on neuromuscular function,
with a particular focus on the SUMO-conjugating enzyme
UBC-9.
Since inhibition of SUMO enzyme expression led to
increased muscle contraction, we expected overexpression
would cause aldicarb resistance, consistent with decreased
muscle contraction. However, overexpression of UBC-9 in all
neurons or only in GABAergic neurons also led to increased
muscle excitation, indicated by aldicarb hypersensitivity, relative to wild type worms or to negative control worms expressing green fluorescent protein (GFP) in pharyngeal cells as a
co-injection marker (Figure 2a and b, Figure S1A). In contrast,
a wild type aldicarb paralysis phenotype was observed for
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Figure 2. GABAergic neuron-specific overexpression of UBC-9 or AOS-1 causes increased muscle excitation. Aldicarb assays were performed on wild
type (WT) animals, animals overexpressing a control plasmid (Mock OE), and animals overexpressing (A) UBC-9 in all neurons (UBC-9 Neuron OE), (B)
UBC-9 in GABAergic neurons only (UBC-9 GABA OE), UBC-9 in cholinergic neurons only (UBC-9 ACh OE), or (C) AOS-1 in GABAergic neurons only
(AOS-1 GABA OE). (Upper panels) Representative timecourses showing the average percentage of young adult worms paralyzed per plate (15-20 worms
per plate, n = 3 plates) on 1 mM aldicarb. (Lower panels) Bar graphs showing cumulative data for worms paralyzed at the 75 minute timepoint (indicated by
* in upper panels). Error bars for all graphs denote s.e.m. of the corresponding dataset. n = total # plates per strain. All bars sharing common letters (a-b)
were determined to be statistically similar using a one-way ANOVA, followed by a Tukey’s post hoc analysis. Neuronal UBC-9 overexpression F(2,
35) = 3.5487, P = .0395; Tukey’s post hoc WT versus Neuronal UBC-9 OE, P = .0362; Mock OE versus Neuronal UBC-9 OE, P = .1412; WT versus Mock OE,
P = .834. GABA neuron-specific UBC-9 overexpression: F(2, 45) = 20.9361, P < .0001; Tukey’s post hoc WT versus UBC-9 GABA OE, P < .0001; Mock OE
versus UBC-9 GABA OE, P < .0001; WT versus Mock OE, P = .6833. ACh neuron UBC-9 overexpression: F(2,24) = 11.7255, P = .0003; Tukey’s post hoc
Mock OE versus UBC-9 ACh OE, P = .7794; Mock OE versus UBC-9 GABA OE, P = .0004; UBC-9 ACh OE versus UBC-9 GABA OE, P = .0023. GABA
neuron-specific AOS-1 overexpression: F(2,24) = 10.093, P = .0007. Tukey’s post hoc WT versus AOS-1 GABA OE, P = .0004, Mock OE versus AOS-1
GABA OE, P = .0736; WT versus Mock OE, P = .0947.

UBC-9 overexpression exclusively in cholinergic (ACh) neurons (Figure 2b, Figure S1B) Together, these data suggest that
too much or too little UBC-9 expression in GABA neurons
can shift the balance of neuromuscular signaling toward excitation. Similar results were observed for GABA neuron-specific
overexpression of AOS-1, suggesting the effects may be due to
global disruption or activation of the SUMOylation pathway
at the NMJ (Figure 2c, Figure S1C).
Given the effects of neuronal UBC-9 expression on muscle
function and the reported roles for SUMOylation on presynaptic proteins and synaptic vesicle release at other synapse
types,10,27 we used quantitative fluorescence imaging of GFPtagged SNB-1/synaptobrevin, a synaptic vesicle associated
v-SNARE protein, to test whether neuronal UBC-9 overexpression alters synaptic vesicle localization in GABAergic or
cholinergic motor neurons. Previous studies have shown that
GFP::SNB-1 expressed under cell type-specific neuronal promoters marks presynaptic sites and correlates with the number
of vesicles at synapses.66,67 For this reason, quantitative imaging
of GFP::SNB-1 has been used extensively to measure synapse
density, as well as serving as a readout of synaptic vesicle accumulation that typically correlates with changes in synaptic

vesicle cycling.48–50,68 Worms with increased GFP::SNB-1
puncta intensity tend to have more vesicles clustered at synapses due to decreased release, whereas decreased GFP::SNB-1
puncta intensity (often coupled with increased interpunctal
axonal fluorescence) correlates with increased vesicle exocytosis
and more signaling.49,50,68,69 Compared to wild type worms,
animals overexpressing UBC-9 in all neurons or only in GABA
neurons had significantly brighter (~40-50%) GFP::SNB-1
synaptic puncta in GABAergic motor neurons, as well as
increased (30-40%) interpunctal fluorescence, compared to
wild type animals (Figure 3a). These effects were not seen for
GFP::SNB-1 in cholinergic motor neurons in animals with
panneuronal or GABAergic neuron-specific overexpression of
UBC-9 (Figure 3b), confirming the cell autonomous effect of
UBC-9 overexpression. Similar effects on GABAergic synaptic
vesicles were seen with AOS-1 overexpression in GABA neurons (Figure 3c). Together, these results demonstrate overexpression of SUMO pathway enzymes causes synaptic vesicle
accumulation in and between synapses in GABAergic neurons,
potentially suggesting a decrease in GABA release that could
explain the increased muscle contraction of the UBC-9 and
AOS-1 overexpressing worms (Figure 2).
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Figure 3. Neuronal UBC-9 or AOS-1 overexpression causes synaptic vesicle accumulation at and between synaptic sites in GABAergic, but not
cholinergic, motor neurons. Wild type (WT) worms or worms with neuronal UBC-9 or AOS-1 overexpression (Neuronal OE), GABAergic neuron-specific
UBC-9 or AOS-1 overexpression (GABA Neuron OE) that also expressed GFP::SNB-1 in (A, C) GABAergic neurons (GABA) or in (B) cholinergic (ACh)
neurons were imaged using a 100× objective. (Upper panels) Representative images of the dorsal nerve cords halfway between the vulva and the tail.
(Lower panels) Quantification of puncta (synaptic) intensity, interpunctal (axonal) fluorescence, puncta width (µm), and puncta density (per 10 µm) ± s.e.m.
Puncta intensity, interpunctal intensity, and puncta width are all shown normalized to wild type. For (A), n = 28 animals imaged for WT, n = 23 for Neuronal
OE, n = 28 for GABA Neuron OE. For (B), n = 30 for WT, n = 25 for Neuronal OE, n = 28 for GABA Neuron OE. For (C), n = 37 for WT; n = 17 for Neuronal OE,
n = 23 for GABA Neuron OE. Young adult worms were used for all images. *P < .05, **P ⩽ .01, ***P ⩽ .001 versus WT, one-way ANOVA with Tukey’s post
hoc test. All other comparisons P > .05.

Since the aldicarb and imaging results were consistent with
decreased GABA signaling, we tested for direct effects on
GABA-dependent behaviors by assessing the UBC-9 and
AOS-1 GABA neuron overexpressing worms for their sensitivity to the GABAA receptor antagonist, PTZ. PTZ is epileptogenic in mammals70,71 and induces seizures in C. elegans with
reduced GABAergic transmission. Such seizures do not occur
in wild type animals or in those with defects only in cholinergic
signaling63,72 The combination of PTZ-induced seizures and
aldicarb hypersensitivity is routinely used to identify mutants
with GABAergic signaling defects.48,63,73 While we observed
some background anterior “head bobbing” behavior in approximately 25% of PTZ-exposed wild type and Mock OE animals
under our assay conditions, 95% of snb-1(md247) mutants, in
which general synaptic transmission is reduced, showed convulsions on PTZ, as expected (Figure 4)63,73,74. Although not as
robust as the response seen with snb-1 mutants, nearly 50% of
animals with UBC-9 GABAergic neuron overexpression and
67% of worms with AOS-1 GABAergic neuron overexpression
exhibited PTZ-induced convulsions (Figure 4)63. These effects
are in line with the moderate hypersensitivity we observed with
the UBC-9 and AOS-1 overexpressing animals in the aldicarb

assay (Figure 2) and provide further support that animals with
SUMO enzyme overexpression have reduced GABAergic
signaling, likely due to decreased GABA release.73
Synaptic proteins, as well as many transcription factors and
other nuclear proteins, are known to be SUMOylated.8,16,17 To
test whether UBC-9 might be able to act directly at synapses,
we imaged animals expressing either GFP::UBC-9 or the processed form of C. elegans SUMO GFP::SMO-1(GG)57 along
with our synaptic vesicle marker mCherry::SNB-148 and performed colocalization analyses. We first observed that both
GFP::UBC-9 and GFP::SMO-1 localized in punctate distributions within the nerve cord, similar to that seen for
mCherry::SNB-1 (Figure 5). To determine whether these
GFP::UBC-9 and GFP::SMO-1 puncta colocalize with
mCherry::SNB-1-labeled synapses, we isolated a single focal
plane from z-stacks taken of the dorsal nerve cords of worms
co-expressing mCherry::SNB-1 and either GFP::UBC-9 or
GFP::SMO-1 and performed quantitative linescan analyses to
determine the percentage of GFP::UBC-9 or GFP::SMO-1
puncta that showed peak overlap with mCherry::SNB-1
puncta. We found that 85.3 % of green GFP::UBC-9 and 87.9
% of green GFP::SMO-1 peaks colocalized with red
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Figure 4. GABAergic neuron-specific overexpression of UBC-9 or AOS-1
causes PTZ-induced seizures, indicative of defects in GABAergic
transmission. Wild type (WT) animals, snb-1(md427) mutants (defective
in general synaptic transmission), animals overexpressing a control
plasmid (Mock OE), animals overexpressing UBC-9 in GABAergic
neurons only (UBC-9 GABA OE), or animals expressing AOS-1 in
GABAergic neurons only (AOS-1 GABA OE) were exposed to plates
containing 10 mg/ml PTZ for 50 minutes. Bar graphs show the mean
percentage of young adult worms per plate exhibiting anterior
convulsions (15-25 worms per plate). Each overlaid dot indicates the
percentage of animals convulsing on one of the individual plates from
which the mean was derived. n = # of plates per strain. Error bars
denote ± SD. All bars sharing common letters (a-b) were determined to be
statistically similar using a one-way ANOVA [F(4,41) = 36.2529, P < .0001]
followed by a Tukey’s post hoc analysis: WT/Mock OE versus snb-1,
P < .0001; WT versus UBC-9 GABA OE, P = .0271; Mock OE versus
UBC-9 GABA OE, P = .0525; WT/Mock OE versus AOS-1 GABA OE
P < .0001; UBC-9 GABA OE versus AOS-1 GABA OE, P = .0535.

mCherry::SNB-1 peaks (Figure 5). Similarly, 84% and 83.4%
of red mCherry::SNB-1 peaks colocalized with green
GFP::UBC-9 and green GFP::SMO-1 peaks, respectively.
This strong colocalization was not due to bleed-through of
fluorophores between channels (Figure S2). Thus, while there
was not perfect colocalization, well over three quarters of
UBC-9 and SMO-1 puncta in the dorsal nerve cord were
found with SNB-1-labeled synapses; likewise, the vast majority
of SNB-1 sites contained UBC-9 and SMO-1.
Since UBC-9 and SMO-1 both localized to synapses where
they could interact to regulate synaptic protein SUMOylation,
we next asked whether the catalytic activity of UBC-9 was necessary for the NMJ effects observed in worms overexpressing
UBC-9. To do this, we mutated the active site of UBC-9 at
cysteine 93, which forms a thioester bond with the activated
SUMO75, to serine (C93S) and compared the aldicarb sensitivity of worms overexpressing wild type UBC-9 and UBC9(C93S) in GABAergic neurons to each other and to that of
wild type animals. The C93S mutation has been shown to render UBC-9 catalytically inactive by preventing thioester bond

formation with activated SUMO.76,77 Worms overexpressing
UBC-9(C93S) in GABA neurons showed hypersensitivity to
aldicarb-induced paralysis compared to mock overexpressing
worms and wild type animals; this hypersensitive phenotype
was similar to that seen with wild type UBC-9 overexpression
(Figure 6a; Figure S3A).
Because overexpression of UBC-9 lacking its SUMOconjugating ability resulted in the same neuromuscular phenotype as did overexpression of wild type UBC-9, the active site
of UBC-9 may not be necessary for the increased muscle contraction observed in UBC-9 overexpressing worms. On the
other hand, because SUMO levels are limiting in cells.78 overexpressing UBC-9 alone may lead to SUMO-limiting effects
where proteins are bound to excess UBC-9 in the presence of
too little free SUMO, causing insufficient SUMOylation and a
UBC-9 dominant negative phenotype. To mitigate any
SUMO-limiting effects, we co-overexpressed wild type UBC-9
with SMO-1(GG) and again performed aldicarb assays.
Co-overexpression of wild type UBC-9 with SMO-1 in
GABA neurons yielded a hypersensitive phenotype relative to
wild type worms (Figure 6b, Figure S3B). The phenotype is
slightly, but not significantly, higher than the levels observed in
worms overexpressing only wild type UBC-9 or only SMO-1.
The more modest effects observed with UBC-9 overexpression
in this experiment compared to previous experiments may be
due to small differences in expression levels, as different lines of
worms had to be used to accommodate the co-expression.
Overall, however, this non-additive phenotype suggests UBC-9
and SMO-1 may be acting in the same pathway in GABAergic
neurons to impact muscle contraction and that ultimately
either too much or too little SUMO enzyme activity may cause
E:I imbalance leading to excess muscle excitation.

Discussion

SUMOylation is an essential part of synaptic transmission for
all animals, as it controls the activity of many proteins necessary for synapse formation and for pre- and post-synaptic
function8,17. Most studies to date, however, have focused on the
role of the SUMO pathway at excitatory glutamatergic synapses. As a result, potential functions for SUMO enzymes in
controlling signaling at different synapse types and the effects
of SUMOylation on E:I balance remain largely unexplored,
despite links between several known SUMOylated neuronal
proteins and diseases involving E:I imbalances. Here, we show
the SUMO-conjugating enzyme UBC-9 can act in inhibitory
motor neurons, where it localizes with SUMO to presynaptic
sites and controls synaptic vesicle localization, to modulate E:I
balance and muscle excitation at the C. elegans NMJ.

Tight regulation of UBC-9 activity is required in
GABAergic neurons to maintain E:I balance
Overall, our data show that misregulation of UBC-9 and
SUMO expression in GABAergic neurons disrupts
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Figure 5. UBC-9 and SMO-1 localize to synaptic sites in GABAergic motor neurons. Young adult worms expressing both mCherry::SNB-1 and either (A)
GFP::UBC-9 or (B) GFP::SMO-1 in GABAergic motor neurons were immobilized and imaged on a Leica DMLB fluorescence microscope at 100X
magnification. (Upper panels) Representative single plane images from 2 µm total depth z-stacks taken of the dorsal nerve cords where neuromuscular
synapses are found. White arrowheads mark sites of colocalization; yellow arrows denote sites with only one marker localized. (Lower panels)
Quantification of the mean percentage of colocalization of peaks of mCherry::SNB-1 colocalization with GFP::UBC-9 and GFP::SMO-1 ± SD generated
from linescans of the dorsal nerve cords. Box and whisker plots show the minima and maxima (whiskers), as well as the first and third quartiles of data
(boxes), divided by the median line. The “X” denotes the mean value of the data set, and circles show individual data points. (n = 27 UBC-9/SNB-1 and
n = 26 SMO-1/SNB-1 animals imaged).

neuromuscular activity. Based on our results, we favor a model
in which UBC-9 acts, likely via its SUMO-conjugation activity, to regulate GABAergic vesicle release and prevent excess
muscle excitation. Several lines of evidence support our proposed model. First, our over- and under-expression experiments suggest tight control of neuronal UBC-9 expression is
critical to maintain proper muscle excitation. In our initial
screen, neuronal knockdown of the SUMO enzyme genes ubc9 or aos-1 led to increased muscle contraction compared to
wild type worms (Figure 1), indicating ubc-9 and aos-1 are necessary to inhibit muscle excitation. Similar increases in muscle
contraction were seen in animals with panneuronal or
GABAergic neuron-specific overexpression of UBC-9, but not
with UBC-9 overexpression in cholinergic neurons (Figure 2),
supporting a specific effect of these enzymes in GABAergic
neurons. Second, overexpression of UBC-9 in all neurons or
just in GABAergic neurons caused synaptic vesicle accumulation at GABAergic motor neuron presynapses, as well as sensitivity to the GABAA receptor antagonist, PTZ (Figures 3 and

4). These results are consistent with decreased GABA release
and with the increased muscle contraction observed in these
animals.48-50 Third, both UBC-9 and SMO-1 co-localized
with synaptic vesicle markers in GABAergic neurons (Figure
5), implying UBC-9 may act locally at presynaptic sites where
it could SUMOylate known or novel synaptic targets to control
synaptic vesicle release. Fourth, the increased muscle contraction seen with overexpression of wild type UBC-9 or the
UBC-9(C93S) mutant indicates the active site of UBC-9 is
not necessary for the NMJ effects of UBC-9 overexpression
(Figure 6a). Given these are overexpression experiments and
that levels of free SUMO in cells are reportedly low,78 both
UBC-9 variants may cause loss of function phenotypes due to
binding and sequestration of UBC-9 targets unable to be
SUMOylated because of catalytic inactivity [e.g., UBC9(C93S)] or insufficient free SUMO (e.g. wild type UBC9).78,79 The fact that overexpression of AOS-1 in GABAergic
neurons also led to increased muscle contraction, synaptic vesicle accumulation and PTZ-induced convulsions (Figures 2–4)
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Figure 6. UBC-9 overexpression effects on NMJ signaling are independent of UBC-9 catalytic activity and are non-additive with co-expression of SMO-1.
Aldicarb assays were performed on wild type (WT) animals, on animals overexpressing a control plasmid (Mock OE), and animals overexpressing (A)
UBC-9 or UBC-9(C93S) or (B) UBC-9, SMO-1(GG), or UBC-9+SMO-1(GG) in GABA neurons. (Upper panels) Representative timecourses showing the
average percentage of young adult worms paralyzed per plate (15-20 worms per plate, n = 3 plates) on 1 mM aldicarb. (Lower panels) Bar graphs
quantifying cumulative data for worms paralyzed at a single timepoint (indicated by * in upper panels). Error bars for all graphs denote s.e.m. of the
corresponding dataset. n = total # plates per strain. All bars sharing common letters (a-b) were determined to be statistically similar using a one-way
ANOVA, followed by a Tukey’s post hoc analysis. (A) ANOVA: F(3,32) = 17.2912, P < .0001; Tukey’s post hoc WT versus UBC-9(C93S), P < .0001; Mock
OE versus UBC-9(C93S), P < .0001; WT versus UBC-9, P = .0002; Mock OE versus UBC-9, P = .0002; UBC-9 versus UBC-9(C93S), P = .9184; WT versus
Mock OE, P = .4934). (B) ANOVA: F(3,40) = 8.4909, P = .0002; Tukey’s post hoc WT versus UBC-9+SMO-1, P < .0001; UBC-9 versus UBC-9+SMO-1,
P = .0589; SMO-1 versus UBC-9+SMO-1, P = .2976.

further supports this model in which SUMO:enzyme stoichiometry is disrupted in the overexpression context rather than a
specific SUMO-independent effect of UBC-9. Fifth and
finally, the non-additive increases in muscle excitation caused
by UBC-9 and SMO-1 co-overexpression suggest these proteins act in the same pathway to impact neuromuscular function and that too much, as well as too little, SUMOylation can
increase signaling for muscle contraction (Figure 6b). Together,
these findings support a role for UBC-9 in GABAergic neurons to control GABA release, prevent excess muscle contraction, and maintain E:I balance. While this is the first study
implicating UBC-9 and the SUMO system at inhibitory presynapses, recent work showed GABAergic neuron-specific
effects of several ubiquitin ligase enzymes in neuromuscular
regulation,48,80,81 highlighting the importance of related protein modification systems in inhibitory neuronal signaling.
How likely is it that GABAergic neurons are the primary
site of UBC-9 action at the NMJ? Our data suggest UBC-9 is

necessary and sufficient in all neurons, and specifically in
GABAergic neurons, to control muscle excitation, where it is
also sufficient to cause PTZ-induced seizures and to alter synaptic vesicle localization in a manner consistent with decreased
GABA release (Figures 1, 2, 3, 4, 6). While is it possible the
knockdown phenotype we observed is due to inhibition of ubc9 or aos-1 in non-neuronal cells, the strain used for the RNAi
experiments expresses high levels of SID-1 dsRNA channels in
neurons, which biases RNAi effects toward these cells.59 When
examining specific neuronal subtypes relevant for NMJ control, we found that overexpression of UBC-9 in GABAergic
neurons increased muscle excitation, whereas there was no
effect of UBC-9 overexpression in cholinergic neurons. The
reason for this GABAergic neuron expression effect remains
unknown; however, our data do not rule out a role in excitatory
cells. One possible explanation for the cell type-specific effects
is that differing levels of UBC-9 expression are achieved with
each of the cell type-specific promoters used for the
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overexpression studies. Similar variability in expression also
could explain the lack of ubc-9 knockdown effects in animals
engineered to allow RNAi only in cholinergic versus only in
GABAergic neurons in our preliminary studies (data not
shown). Alternatively, it is possible there is more compensation
for effects on neuromuscular transmission in the cholinergic
neurons. Unlike GABAergic neurons, which only synapse with
postsynaptic muscle, cholinergic motor neurons directly signal
to both GABAergic motor neurons and to muscle cells to
maintain E:I balance.82 Similar GABAergic neuron-specific
effects to those we observed were seen with inhibition of the
anaphase promoting complex and EEL-1 ubiquitin ligases, the
F-box protein MEC-15 FBXW9, as well as the cell adhesion
molecule CASY-1, in prior studies at this synapse.48,80,81,83
These collective results demonstrate GABAergic neuron-specific regulation is possible, and even common, and that the
aldicarb paralysis assay may be particularly sensitive to defects
in inhibitory neurons.50
We found that GABAergic neuron-specific overexpression
not only of wild type UBC-9 but also the C93S mutant
increased muscle excitation (Figure 6a), suggesting UBC-9’s
effects may be independent of its catalytic activity; however,
because of the overexpression context, we believe this does not
necessarily reflect a SUMOylation-independent role for
endogenous UBC-9 at this synapse. Rather, the increased muscle contraction seen with overexpression of either wild type
UBC-9 or UBC-9(C93S) may actually be due to a loss of function of the enzyme in both cases due to sequestration of UBC-9
targets unable to be SUMOylated. In support of this idea, a
yeast two-hybrid assay performed by Eloranta and Hurst
(2002) showed the human Ubc9(C93S) mutant is severely
compromised in its interaction with SUMO-1 but can still
interact with its SUMOylation target, the AP-2 transcription
factor, as efficiently as wild type UBC9, leading the authors to
suggest a dominant negative mechanism.79 Similarly, because
free SUMO levels are reported to be limiting in cells,78 it possible that, when overexpressed alone, wild type UBC-9 binds to
a greater number of its protein targets but lacks sufficient free
SUMO to SUMOylate those proteins efficiently, resulting in a
similar dominant negative effect. Further supporting this possibility, we also found that UBC-9 and SMO-1 co-expression
in GABAergic neurons caused non-additive increases in muscle contraction (Figure 6b), indicating these proteins likely
exert their effects on NMJ function through a common pathway, which would be expected to involve SUMOylation. Our
additional observation that neuronal knockdown or GABAergic
neuron overexpression of the E1 SUMO-activating enzyme
subunit AOS-1 also resulted in increased muscle contraction,
synaptic vesicle accumulation, and PTZ sensitivity (Figures 1–
4) further indicates that the expression and activity of multiple
SUMO enzymes must be precisely regulated for proper NMJ
function. Because the Aos1-Uba2 heterodimeric E1 enzyme
must bind Ubc9 to enforce SUMO transfer to the E2,32 the
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UBC-9 and AOS-1 overexpression phenotypes in our system
also could be due to an imbalance in UBC-9:AOS-1-UBA-2
stoichiometry again leading to dominant negative-type substrate sequestration effects. Together, while SUMOylationindependent effects of UBC-9 have been previously
demonstrated84–87 and cannot fully be ruled out, these data
suggest the phenotypes seen with wild type UBC-9 overexpression in our study are most likely due to SUMO-limiting
effects and/or incorrect stoichiometry of SUMO pathway
enzymes rather than indicating an endogenous non-catalytic
UBC-9 function at this synapse.
When considering our data in light of a model involving
UBC-9’s SUMOylation activity, it appears that either too
much or too little SUMOylation can lead to increased muscle
excitation. Too little SUMOylation could be occurring in the
case of ubc-9 knockdown and in the case of UBC-9 or UBC9(C93S) expression alone through the dominant negative and
substrate sequestration mechanisms discussed above.
Conversely, if UBC-9 acts in a common pathway with SMO-1
when the 2 are overexpressed together, it is likely due to excess
SUMOylation, since conjugation-independent effects of
SMO-1 and UBC-9 would not necessarily be expected to
depend on one another. Previous work in C. elegans showed
that although muscle-specific overexpression of the non-conjugatable SMO-1(GA) or human SUMO-2(GA) caused some
defects in C. elegans body morphology, these were less severe
than the defects seen with wild type SMO-1 or SUMO-1
overexpression.45 This suggests the majority of effects of
SMO-1 overexpression result from increased target
SUMOylation, which has been detected with SUMO overexpression in other systems,78 rather than non-specific or indirect
effects. Other studies described additional cases in which either
the excess or absence of synaptic protein SUMOylation causes
similar defects in synapse formation or function. For example,
SUMOylation of the active zone protein, Rim1α, is required
for action potential-evoked synaptic vesicle exocytosis and calcium entry, whereas non-SUMOylated Rim1α aids in synaptic
vesicle docking and priming. Thus, either too much or too little
Rim1α SUMOylation can decrease synaptic vesicle release.10
Likewise, SUMOylated syntaxin1A slows endocytosis, generally under intense stimulation, while non-SUMOylated syntaxin1A is a critical part of the SNARE complex required for
membrane fusion during exocytosis.9 As our experiments
focused on steady state neuromuscular activity in adult organisms rather than muscle excitation achieved under specific
stimulation conditions, it is possible subtle differences in the
nature of the defects caused by excess or reduced SUMOylation,
if both occurred in our system, all manifested as increased muscle excitation. Future studies examining the SUMOylation levels of specific proteins in GABAergic neurons under
knockdown and overexpression conditions and using electrophysiology or calcium imaging to more directly measure synaptic transmission will be needed to fully delineate the
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mechanisms by which UBC-1 and SMO-1 affect muscle
excitation.

UBC-9 can control GABAergic vesicle localization
potentially through local presynaptic effects
Although we did not explore specific SUMOylation targets in
this study, our imaging data provide some clues as to the potential mechanism by which UBC-9 misexpression impacts
GABAergic signaling to control E:I balance. Using quantitative imaging of GFP::SNB-1, we found worms with panneuronal or GABAergic neuron-specific UBC-9 overexpression
accumulated synaptic vesicles relative to wild type worms in
GABAergic but not in cholinergic motor neurons (Figure 3a).
Increased GFP::SNB-1 puncta intensity typically reflects
decreased exocytosis of vesicles into the synaptic cleft and correlates with decreased signaling.48–50 Conversely, increased
interpunctal fluorescence often coincides with endocytic
defects, as this fluorescence is indicative of GFP::SNB-1containing vesicles that have fused with the membrane, allowing the GFP::SNB-1 to diffuse away from the synapse.49 The
fact that we observed increases in both punctal and interpunctal GFP::SNB-1 fluorescence could indicate that the UBC-9
overexpressing animals actually have increased release and/or
increased levels of GABA-containing vesicles. Alternatively, it
is possible UBC-9 overexpression affects aspects of both synaptic vesicle exo- and endocytosis. While we cannot exclude
either of these possibilities, or more complicated multicellular
effects on both cholinergic and GABAergic signaling, a net
decrease in GABA release is most consistent with the increased
muscle contraction and the GABA-dependent seizure behaviors we observed in the aldicarb and PTZ assays, respectively,
following UBC-9 overexpression (Figures 2 and 4). Accordingly,
as loss of function of either the calcium channel subunit
UNC-2 or the anaphase-promoting complex ubiquitin ligase,
both of which are required for synaptic vesicle release from
motor neurons, exhibit similar increases in both GFP::SNB-1
punctal and interpunctal fluorescence,48,88 it is possible the
increases we observed in UBC-9 overexpressing animals
resulted from synaptic vesicle buildup that led to spillover
beyond synaptic sites. Such spillover may or may not be due to
overall increases in the total number of vesicles and/or to
defects in vesicle trafficking or maintenance at synapses.48
Importantly, these presynaptic effects may be accompanied
by postsynaptic changes in GABA receptor levels or sensitivity,
as mutants lacking UNC-49 GABAA receptors are both
aldicarb hypersensitive and exhibit PTZ-induced convulsions.50,72 Increases in GABAA receptors have been observed in
response to decreased GABA release in C. elegans lacking the
function of the anaphase promoting complex, and the opposing
homeostatic responses to increases in GABA release have been
reported in other systems.48,89 While it is possible increased
GABA release could be leading to decreased GABA receptor

13

expression or sensitivity (or vice versa, if there are cell nonautonomous effects of our neuronally expressed SUMO
enzymes) to cause the behavioral responses we observe, such
changes would be expected to maintain relatively wild type levels of GABAergic signaling. Thus, while further exploration of
the homeostatic effects of neuronal UBC-9 overexpression on
muscle excitation, as well as additional roles for SUMO
enzymes within the muscle cells themselves, will be of interest
to explore, our current data most directly support a presynaptic
role for the overexpression effects.
Not only do our data suggest UBC-9 expression levels critically regulate synaptic vesicle localization and potentially
release, but by imaging worms co-expressing GFP::UBC-9 or
GFP::SMO-1 with mCherry::SNB-1 in GABAergic neurons,
we observed strong localization of UBC-9 and SMO-1 at presynaptic sites (Figure 4). Given that we also observe
GFP::UBC-9 and GFP::SMO-1 in the cell bodies (data not
shown), as well as at synapses and more diffusely along the
dorsal and ventral nerve cords, our results do not preclude the
function of overexpressed UBC-9 in the nucleus or elsewhere
within the motor neurons in this context. However, the fact
that UBC-9 and SMO-1 can localize to synapses is consistent
with a model in which UBC-9 and SMO-1 regulate overall
neuromuscular activity and synaptic vesicles in GABAergic
neurons by acting directly at presynaptic sites through effects
on synaptic proteins. This model is supported by prior studies
demonstrating stimulation-dependent localization of mammalian Aos1, Ubc9, as well as other SUMOylation and deSUMOylation machinery, to hippocampal presynaptic sites, where
increased SUMOylation of synaptic proteins and effects on
synaptic vesicle release are also observed.14,15,25 In hippocampal
spines, activity-dependent Ubc9 localization occurs in response
to an increase in its Protein Kinase C (PKC)-phosphorylated
substrates and is dependent upon its catalytic cysteine.13 It will
be of interest to determine whether activity-dependent localization of C. elegans SUMOylation machinery to GABAergic
presynapses also occurs and what domains are required for this
localization. Mammalian Ubc9 is also known to be regulated
by acetylation and SUMOylation, modifications that can alter
its substrate specificity and thus potentially its localization.30,90
Whether C. elegans UBC-9 is similarly regulated remains to be
explored.
As noted above, work done at glutamatergic synapses in
other systems uncovered several SUMOylated presynaptic
proteins, including Rim1α, synaptotagmin-1, synapsin1A,
and syntaxin1A, which could mediate the effects of UBC-9 at
GABAergic presynapses to regulate synaptic vesicle release,
supporting the relevance of UBC-9 activity to synaptic plasticity9,10,27,28 and to learning and memory.37 Defects in synaptic protein SUMOylation are also linked to neurological and
neurodegenerative diseases in which E:I imbalances occur.16,91
For example, the A548T mutation in synapsin1A, which is
strongly associated with autism and epilepsy,91 causes reduced
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synapsin1A SUMOylation leading to a reduction in the
releasable synaptic vesicle pool following neuronal stimulation
in mouse hippocampal neuron cultures. It will be of interest to
determine whether the defects in vesicle exocytosis due to loss
of synapsin1A SUMOylation contribute to the disease phenotype in patients with the A548T mutation and whether
SUMOylation of synapsin1A or other synaptic vesicle-associated proteins is critical for transmission at GABAergic
synapses.

Conclusions and Future Directions

Overall, our data are consistent with a role for the SUMO
pathway, and specifically, the SUMO-conjugating enzyme
UBC-9, in promoting E:I balance at the C. elegans NMJ by
acting locally at presynaptic sites in GABA neurons to control
GABAergic signaling to prevent excess muscle excitation.
Although additional studies are required to determine the precise mechanism underlying UBC-9 and other SUMO enzyme
effects at this synapse, to our knowledge, this work is the first
to demonstrate presynaptic function and localization of both
UBC-9 and SMO-1 at inhibitory GABAergic synapses in any
organism. It also further supports the increasingly prevalent
notion that tight regulation of the SUMO enzyme system is
critical for E:I balance within the nervous system. Given that
AOS-1 overexpression causes similar effects to that seen with
UBC-9, additional investigation into the effects of other
SUMOylating and de-SUMOylating enzymes will be of interest to ascertain the full extent of SUMO pathway influence at
the NMJ. Future studies identifying targets of SUMOdependent and/or independent functions of UBC-9 at this
synapse, associated E3 SUMO ligases and/or deubiquitinating
enzymes, and potential regulation of UBC-9 and other SUMO
pathway components by activity, oxidative stress, and hormone
signaling, all of which can impact neuronal SUMOylation,16,53,92
will be critical for understanding how UBC-9 regulates presynaptic function in GABAergic neurons. Such studies will
inform further investigation into the roles Ubc9 and the
SUMO system play in mammalian GABAergic neurons and,
in so doing, will contribute to our understanding of E:I balance
misregulation in neurological and neurodegenerative diseases
in which the SUMO pathway is disrupted.
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